PIB Bulletin Update on COVID-19

PIB News Update:

• India’s Active Caseload Declines for the Second Consecutive day
• WHO has not associated the term “Indian Variant” with B.1.617, now classified as Variant of Concern
• Government to ramp up availability of Amphotericin B – to fight Mucormycosis

#Unite2FightCorona

#IndiaFightsCorona

 

 

 

PRESS INFORMATION BUREAU

MINISTRY OF INFORMATION AND BROADCASTING

GOVERNMENT OF INDIA

 

 

 

India’s Active Caseload Declines for the Second Consecutive day

 

• New Recoveries outnumber Daily New COVID Cases for the Second Consecutive day
• India’s Cumulative Vaccination Coverage exceeds 17.5 Crore
• More than 30 lakh beneficiaries of age group 18-44 Vaccinated so far
• The National Recovery Rate is 83.04%.
• The National Mortality Rate currently stands at 1.09%.

For details: https://pib.gov.in/PressReleasePage.aspx?PRID=1717870

 

WHO has not associated the term “Indian Variant” with B.1.617, now classified as Variant of Concern

This is to clarify that WHO has not associated the term “Indian Variant” with the B.1.617 variant of the coronavirus in its 32 page document.

For Details :https://pib.gov.in/PressReleasePage.aspx?PRID=1717876

Ministry of Power takes proactive measures to ensure 24×7 power supply to Oxygen Power Plants in the Country

In view of the pan India impact of the second wave of corona virus pandemic across the country and the manifold rise in oxygen demand for both medical facilities and for home treatment of patients , the Ministry of Power has undertaken a number of pro-active preventive and remedial measures to ensure that there is uninterrupted power supply to Oxygen Plants by the State Utilities

For Details: https://pib.gov.in/PressReleasePage.aspx?PRID=1717861

 

Government take steps to ramp up availability of Amphotericin B – to fight Mucormycosis
A sudden increase in demand has been observed in some states for Amphotericin B which is being actively prescribed by the physicians to patients suffering from Mucormycosis, a post COVID complication. The Government of India is therefore engaging with the manufacturers to ramp up production of the drug. The supply position is expected to improve with extra imports of this drug and increase in its production domestically.

For Details: https://pib.gov.in/PressReleasePage.aspx?PRID=1717864

 

 

 

PIB FACT CHECK

 

 

 

Is #Remdesivir a life saving drug in #COVID19#PIBFactree

It is an experimental investigational drug that Is advisable for people who are moderately sick and are receiving oxygen.
Studies do not show mortality reduction with this drug. pic.twitter.com/CfdAo8TVGJ

— PIB Fact Check (@PIBFactCheck) May 11, 2021